Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
Ramin Rafie, MD is an Internist trained in Geriatric, Hospice & Palliative Medicine.Dr. Rafie was born in Iran and grew up in Los Angeles,...
Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role...
Mike Ricci leads Spect, a Y Combinator startup focused on combining eye-care diagnostics and artificial intelligence.
